Provided by Tiger Trade Technology Pte. Ltd.

Oxford

37.74
0.0000
Volume:254.19K
Turnover:9.65M
Market Cap:561.47M
PE:-14.37
High:38.80
Open:37.78
Low:37.61
Close:37.74
52wk High:51.61
52wk Low:30.57
Shares:14.88M
Float Shares:14.30M
Volume Ratio:0.86
T/O Rate:1.78%
Dividend:2.77
Dividend Rate:7.34%
EPS(TTM):-2.6264
EPS(LYR):-1.8639
ROE:-7.01%
ROA:0.94%
PB:1.07
PE(LYR):-20.25

Loading ...

Oxford Nanopore Expands Share Capital Through Option Exercises and Remuneration Schemes

TIPRANKS
·
Jul 01

Oxford Biomedica Confirms 121 Million Voting Rights in Updated Share Capital

TIPRANKS
·
Jul 01

Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial

GlobeNewswire
·
Jun 29

Oxford Industries Shareholders Approve Directors and Incentive Plan

TIPRANKS
·
Jun 27

Oxford Industries Shareholders Approve Amended Long-term Stock Incentive Plan, Adding 750,000 Shares

Reuters
·
Jun 27

Oxford Instruments Tightens Share Base with Latest Buyback Tranche

TIPRANKS
·
Jun 26

Oxford Biomedica price target lowered to 1,140 GBp at RBC Capital

TIPRANKS
·
Jun 25

Oxford Instruments Publishes 2026 Annual Report and Schedules AGM

TIPRANKS
·
Jun 23

Oxford Biomedica Expands Share Capital with New Employee Scheme Allotments

TIPRANKS
·
Jun 22

Oxford Instruments Cuts Share Count Further Through Ongoing Buyback

TIPRANKS
·
Jun 19

Oxford Industries management to meet with KeyBanc

TIPRANKS
·
Jun 19

Oxford Metrics director boosts stake with share purchase

TIPRANKS
·
Jun 18

Kyle Mikson Reiterates Buy on Oxford Nanopore, Sees Differentiated Growth with Unchanged 200p Price Target

TIPRANKS
·
Jun 18

Oxford Metrics chair and associate lift stake with fresh share purchases

TIPRANKS
·
Jun 17

Oxford Biomedica Seeks LSE Admission for New Employee Incentive Shares

TIPRANKS
·
Jun 17

Oxford Metrics Sets Ambitious Growth and Margin Targets in Strategy Update

TIPRANKS
·
Jun 17

Oxford Industries Is Maintained at Neutral by Citigroup

Dow Jones
·
Jun 17

Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026

GlobeNewswire
·
Jun 16

Oxford Lane reports NAV per share of $11.40-$11.70 as of May 31

TIPRANKS
·
Jun 15

Top Executive Makes Bold Insider Move at Oxford Industries

TIPRANKS
·
Jun 13